Featured News

Akturk and McKee review emerging type 1 diabetes technologies and therapeutics 

On August 19, Halis Kaan Akturk, MD of the Barbara Davis Center for Diabetes at University of Colorado and Alexis M. McKee, MD of the Division of Endocrinology, Metabolism and Lipid Research at Washington University School of Medicine, had their review titled “Emerging Technologies and Therapeutics for Type 1 Diabetes,” published online by Science Direct.

Over the last decade, diabetes technologies have evolved in life-changing ways for those with type 1 diabetes. In addition, with the use of stem cell research and gene editing, the journey of finding a cure has progressed rapidly. 

In their review, the authors discuss various diabetes technologies, such as continuous glucose monitoring (CGM), hybrid closed loop systems, and smart insulin pens. Additionally, they address present day disparities in utilization of diabetes technologies in individuals with type 1 diabetes. 

With progressive therapies also on the rise, Drs. Akturk and McKee share that “newer adjunctive therapies are likely to be approved to decrease insulin requirements, weight, and A1c.” Further stating that in the meantime, providers should focus on “decreasing disparities in diabetes technology use, encouraging minorities to be involved in clinical trials,” and assisting patients in finding which diabetes technologies work best for them. 

Halis Kaan Akturk, Alexis M. McKee. Emerging Technologies and Therapeutics for Type 1 Diabetes. Endocrinology and Metabolism Clinics of North America. 2023. ISSN 0889-8529. https://doi.org/10.1016/j.ecl.2023.07.002